Our Story

A Dartmouth Spin-Off

In 2015 Sol Diamond, Lidia Valdés and Brad Ficko set out to revolutionize medical diagnostics and founded Lodestone Biomedical out of a basement laboratory at Dartmouth College.

Early on Lodestone aimed to bring low-cost, high-sensitivity magnetic detection methods into the medical device market. Our goal was not to incrementally improve existing diagnostics, but to measure what was previously impossible to detect.

In close collaboration with advisors and clinical collaborators, we refined our magnetic detection methods over the years to the cytokine monitoring system we offer today.

Our Mission

A personal guide to better health

Our mission at Lodestone is to improve patient outcomes by helping medical professionals make treatment decisions earlier. We believe, that listening to the individual patient's response on a cellular level will guide physicians to take the best informed course of action.

To measure the unknown

If we want to develop the treatments of tomorrow we need to understand the molecular language of the body, the immune system, and the disease in each individual case. Understanding the biochemical effects of novel treatments on a cellular level will accelerate pre-clinical research, identify the best target population and translate to saver and more affordable clinical products.

About the Name

Lodestone (/ˈlōdˌstōn/, noun) a naturally occurring magnetic rock composed of the mineral magnetite.

In ancient times, explorers used lodestones to make magnetic compasses for navigation on land and at sea. This extraordinary history of magnetite is reflected in the name "Lodestone", which means "leading stone.”

Today magnetite forms the core of Lodestone Biomedical's magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology. Our biosensors serve as a "molecular compass" for cancer immunotherapy drug development from bench to bedside.